Affiliation:
1. Laboratory for Information Technology in Pharmacology and Computer Modeling of Drugs, Research Center for Innovative Medicines, Volgograd State Medical University, 39 Novorossiyskaya Street, Volgograd 400087, Russia
2. Department of Pharmacology and Bioinformatics, Volgograd State Medical University, 20 KIM Street, Volgograd 400001, Russia
3. Laboratory of Experimental Pharmacology, Volgograd Medical Research Center, 1 Pavshikh Bortsov Square, Volgograd 400131, Russia
Abstract
A classification consensus ensemble multitarget neural network model of the dependence of the anxiolytic activity of chemical compounds on the energy of their docking in 17 biotargets was developed. The training set included compounds thathadalready been tested for anxiolytic activity and were structurally similar to the 15 studied nitrogen-containing heterocyclic chemotypes. Seventeen biotargets relevant to anxiolytic activity were selected, taking into account the possible effect on them of the derivatives of these chemotypes. The generated model consistedof three ensembles of artificial neural networks for predicting three levels of anxiolytic activity, with sevenneural networks in each ensemble. A sensitive analysis of neurons in an ensemble of neural networks for a high level of activity made it possible to identify four biotargets ADRA1B, ADRA2A, AGTR1, and NMDA-Glut, which were the most significant for the manifestation of the anxiolytic effect. For these four key biotargets for 2,3,4,5-tetrahydro-11H-[1,3]diazepino[1,2-a]benzimidazole and [1,2,4]triazolo[3,4-a][2,3]benzodiazepine derivatives, eight monotarget pharmacophores of high anxiolytic activity were built. Superposition of monotarget pharmacophores built two multitarget pharmacophores of high anxiolytic activity, reflecting the universal features of interaction 2,3,4,5-tetrahydro-11H-[1,3]diazepino[1,2-a]benzimidazole and [1,2,4]triazolo[3,4-a][2,3]benzodiazepine derivatives with the most significant biotargets ADRA1B, ADRA2A, AGTR1, and NMDA-Glut.
Subject
Drug Discovery,Pharmaceutical Science,Molecular Medicine
Reference37 articles.
1. World Health Organization (2021). Mental Health Atlas 2020, World Health Organization. Available online: https://www.who.int/publications/i/item/9789240036703.
2. Generalized Anxiety Disorder;DeMartini;Ann. Intern. Med.,2019
3. Treatment of anxiety disorders;Bandelow;Dialogues Clin. Neurosci.,2017
4. Combination therapy with neuropeptides for the treatment of anxiety disorder;Gupta;Neuropeptides,2021
5. Tyagi, R., Singh, A., Chaudhary, K.K., and Yadav, M.K. (2022). Bioinformatics: Methods and Applications, Academic Press.